Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC brain tumor group study 26951

Journal of Clinical Oncology

Volumn 31, Issue 3, 2013, Pages 344-350

  Van Den Bent, Martin J ^a   Brandes, Alba A ^g   Taphoorn, Martin J B ^b,c   Kros, Johan M ^a   Kouwenhoven, Mathilde C M ^a   Delattre, Jean Yves ^h   Bernsen, Hans J J A ^d   Frenay, Marc ⁱ   Tijssen, Cees C ^e   Grisold, Wolfgang ^j   Sipos, László ^k   Enting, Roelien H ^a,f   French, Pim J ^a   Dinjens, Winand N M ^a   Vecht, Charles J ^b   Allgeier, Anouk ^l   Lacombe, Denis ^l   Gorlia, Thierry ^l   Hoang Xuan, Khê ^h  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^e CPRLab   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g Azienda USL di Bologna   (Italy)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ CENTRE ANTOINE LACASSAGNE   (France)

^j KAISER FRANZ JOSEF HOSPITAL   (Austria)

^k Institute of Neurosurgery   (Hungary)

^l EORTC DATA CENTER   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; VINCRISTINE;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME DELETION; DNA METHYLATION; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RADIATION DOSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GENE DELETION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LOMUSTINE; OLIGODENDROGLIOMA; PROCARBAZINE; VINCRISTINE;

EID: 84873345824     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.2229     Document Type: Article

References (37)

1. Cairncross G, Macdonald D, Ludwin S, et al: Chemotherapy for anaplastic oligodendroglioma: National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:2013-2021, 1994
2. van den Bent MJ, Kros JM, Heimans JJ, et al: Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy: Dutch Neuro-Oncology Group. Neurology 51:1140-1145, 1998 (Pubitemid 28473415)
3. van den Bent MJ, Carpentier AF, Brandes AA, et al: Adjuvant PCV improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715-2722, 2006 (Pubitemid 46630567)
4. Cairncross G, Berkey B, Shaw E, et al: Phase III trial of chemotherapy plus radiotherapy versus radiotherapy alone for pure and mixed anaplastic oligodendroglioma (RTOG 9402): Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714, 2006 (Pubitemid 46630566)
5. Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998 (Pubitemid 28482012)
6. van den Bent MJ, Looijenga LH, Langenberg K, et al: Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97:1276-1284, 2003 (Pubitemid 36237315)
7. van den Bent MJ, Dubbink HJ, Sanson M, et al: MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: A report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 27:5881-5886, 2009
8. van den Bent MJ, Dubbink HJ, Marie Y, et al: IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16:1597-1604, 2010
9. Kleihues P, Burger PC, Scheithauer BW: Histological Typing of Tumours of the Central Nervous System. New York, NY, Springer-Verlag, 1993
10. Kouwenhoven MC, Gorlia T, Kros JM, et al: Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol 11:737-746, 2009
11. Idbaih A, Dalmasso C, Kouwenhoven M, et al: Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. J Neurooncol 103:221-230, 2011
12. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990 (Pubitemid 20195640)
13. Peto R, Peto J: A symptotically efficient rank invariant test procedures (with discussion). J R Statist Soc A 135:185-198, 1972
14. Taphoorn MJ, van den Bent MJ, Mauer ME, et al. Health-related quality of life in patients treated foranaplasticoligodendrogliomawithadjuvant chemotherapy: Results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol 25:5723-5730, 2007
15. van den Bent MJ: Interobserver variation of the histopathological diagnosis in clinical trials on glioma: A clinician's perspective. Acta Neuropathol 120:297-304, 2010
16. Giannini C, Burger PC, Berkey BA, et al: Anaplastic oligodendroglial tumors: Refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 18:360-369, 2008 (Pubitemid 351782844)
17. Kros JM, Gorlia T, Kouwenhoven MC, et al: Panel review of anaplastic oligodendroglioma from EORTC trial 26951: Assessment of consensus in diagnosis, influence of 1p/19q loss and correlations with outcome. J Neuropathol Exp Neurol 66:545-551, 2007 (Pubitemid 46869696)
18. Coons SW, Johnson PC, Scheithauer BW, et al: Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381-1391, 1997
19. Burger PC: What is an oligodendroglioma? Brain Pathol 12:257-259, 2002 (Pubitemid 34259927)
20. Rothwell PM: External validity of randomised controlled trials: "To whom do the results of this trial apply?" Lancet 365:82-93, 2005 (Pubitemid 40082150)
21. Brandes AA, Tosoni A, Vastola F, et al: Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy: A Phase II study. Cancer 101:2079-2085, 2004 (Pubitemid 39425385)
22. Kouwenhoven MC, Kros JM, French PJ, et al: 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer 42:2499-2503, 2006 (Pubitemid 44468379)
23. 22a. Cairncross G, Wang M, Shaw E, et al: Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402. J Clin Oncol 31:337-343, 2013
24. Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812, 2008
25. Balss J, Meyer J, Mueller W, et al: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597-602, 2008
26. Watanabe T, Nobusawa S, Kleihues P, et al: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149-1153, 2009
27. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005 (Pubitemid 40349502)
28. Noushmehr H, Weisenberger DJ, Diefes K, et al: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522, 2010
29. van den Bent MJ, Gravendeel LA, Gorlia T, et al: A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: A report from EORTC study 26951. Clin Cancer Res 17:7148-7155, 2011
30. Laffaire J, Everhard S, Idbaih A, et al: Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro Oncol 13:84-98, 2011
31. Turcan S, Rohle D, Goenka A, et al: IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479-483, 2012
32. Figueroa ME, Abdel-Wahab O, Lu C, et al: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553-567, 2010
33. Lu C, Ward PS, Kapoor GS, et al: IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474-480, 2012
34. Wick W, Hartmann C, Engel C, et al: NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874-5880, 2009
35. Brada M, Stenning S, Gabe R, et al: Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 28:4601-4608, 2010
36. Douw L, Klein M, Fagel SS, et al: Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: Long-term follow-up. Lancet Neurol 8:810-818, 2009
37. Abrey LE, Louis DN, Paleologos N, et al: Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol 9:314-318, 2007 (Pubitemid 47169664)